BR112013010829A2 - composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma - Google Patents

composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma

Info

Publication number
BR112013010829A2
BR112013010829A2 BR112013010829A BR112013010829A BR112013010829A2 BR 112013010829 A2 BR112013010829 A2 BR 112013010829A2 BR 112013010829 A BR112013010829 A BR 112013010829A BR 112013010829 A BR112013010829 A BR 112013010829A BR 112013010829 A2 BR112013010829 A2 BR 112013010829A2
Authority
BR
Brazil
Prior art keywords
approximately
pharmaceutical composition
provide pain
intravenous pharmaceutical
inflammation relief
Prior art date
Application number
BR112013010829A
Other languages
English (en)
Other versions
BR112013010829B1 (pt
BR112013010829B8 (pt
Inventor
Atkinson Hartley Campbell
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013010829(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of BR112013010829A2 publication Critical patent/BR112013010829A2/pt
Publication of BR112013010829B1 publication Critical patent/BR112013010829B1/pt
Publication of BR112013010829B8 publication Critical patent/BR112013010829B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma. uma composição intravenesoa para proporcionar alívio da dor e/ou a inflamação, a composição tendo ibuprofeno e paracetamol em combinação para fornecer a um ser humano em cada dose: a) aproximadamente 125 mg a aproximadamente 175 mg de ibuprofeno em combinação com aproximadamente 475 mg a aproximadamente 525 mg de paracetamol; ou; b) aproximadamente 275 mg a aproximadamente 325 mg de ibuprofeno em combinação com aproximadamente 975 mg a aproximadamente 1025 mg de paracetamol.
BR112013010829A 2010-11-04 2011-10-26 Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação BR112013010829B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
NZ589011 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (3)

Publication Number Publication Date
BR112013010829A2 true BR112013010829A2 (pt) 2016-08-16
BR112013010829B1 BR112013010829B1 (pt) 2021-12-21
BR112013010829B8 BR112013010829B8 (pt) 2021-12-21

Family

ID=46024668

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010829A BR112013010829B8 (pt) 2010-11-04 2011-10-26 Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação

Country Status (27)

Country Link
US (4) US20130225685A1 (pt)
EP (1) EP2635269B1 (pt)
JP (2) JP2013541583A (pt)
KR (1) KR101900520B1 (pt)
CN (2) CN103298464A (pt)
AU (1) AU2011324137B2 (pt)
BR (1) BR112013010829B8 (pt)
CA (1) CA2814057C (pt)
CL (1) CL2013001250A1 (pt)
CO (1) CO6771406A2 (pt)
CY (1) CY1123398T1 (pt)
DK (1) DK2635269T3 (pt)
ES (1) ES2742373T3 (pt)
HR (1) HRP20191489T1 (pt)
HU (1) HUE045442T2 (pt)
LT (1) LT2635269T (pt)
MX (2) MX367209B (pt)
MY (1) MY160572A (pt)
NZ (1) NZ609727A (pt)
PH (1) PH12021550804A1 (pt)
PL (1) PL2635269T3 (pt)
PT (1) PT2635269T (pt)
RS (1) RS59258B1 (pt)
RU (2) RU2013123646A (pt)
SG (1) SG189319A1 (pt)
SI (1) SI2635269T1 (pt)
WO (1) WO2012060719A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2814057C (en) 2010-11-04 2022-02-01 Aft Pharmaceuticals Limited Intravenous composition comprising paracetamol and ibuprofen
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
CA3069158A1 (en) * 2017-07-10 2019-01-17 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US11197830B2 (en) * 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3990895A (en) * 1995-12-05 1997-06-27 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
ES2253326T3 (es) * 2001-11-02 2006-06-01 Cumberland Pharmaceuticals Inc. Composicion farmaceutica de acido 2-(4-isobutilfenilo)propionico.
WO2004093864A1 (en) * 2003-03-21 2004-11-04 Mcneil-Ppc, Inc. Non-steroidal anti-inflammatory drug dosing regimen
US20080275125A1 (en) * 2004-07-07 2008-11-06 Aft Pharmaceuticals Limited Combination Composition
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
WO2008051759A1 (en) * 2006-10-20 2008-05-02 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
JP2012505830A (ja) * 2008-10-14 2012-03-08 エイエフティ ファーマスーティカルズ リミテッド 医薬品及び医薬品治療
ES2823249T3 (es) * 2009-03-12 2021-05-06 Cumberland Pharmaceuticals Inc Administración de ibuprofeno por vía intravenosa
SG186388A1 (en) * 2010-07-07 2013-01-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
CA2814057C (en) 2010-11-04 2022-02-01 Aft Pharmaceuticals Limited Intravenous composition comprising paracetamol and ibuprofen
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛

Also Published As

Publication number Publication date
JP2013541583A (ja) 2013-11-14
WO2012060719A1 (en) 2012-05-10
MY160572A (en) 2017-03-15
LT2635269T (lt) 2019-09-10
JP2017132791A (ja) 2017-08-03
CN103298464A (zh) 2013-09-11
CL2013001250A1 (es) 2013-08-30
KR20140025314A (ko) 2014-03-04
ES2742373T3 (es) 2020-02-14
EP2635269A1 (en) 2013-09-11
PT2635269T (pt) 2019-09-04
HUE045442T2 (hu) 2019-12-30
AU2011324137A1 (en) 2013-05-02
EP2635269A4 (en) 2014-09-17
US20160235695A1 (en) 2016-08-18
US11896567B2 (en) 2024-02-13
JP6353577B2 (ja) 2018-07-04
SI2635269T1 (sl) 2019-10-30
KR101900520B1 (ko) 2018-09-19
CN107519159A (zh) 2017-12-29
US11446266B2 (en) 2022-09-20
RS59258B1 (sr) 2019-10-31
SG189319A1 (en) 2013-05-31
HRP20191489T1 (hr) 2019-11-15
MX2013005113A (es) 2013-06-03
RU2013123646A (ru) 2014-12-10
CY1123398T1 (el) 2021-10-29
US20190029982A1 (en) 2019-01-31
CA2814057C (en) 2022-02-01
BR112013010829B1 (pt) 2021-12-21
CA2814057A1 (en) 2012-05-10
US20230000805A1 (en) 2023-01-05
PL2635269T3 (pl) 2019-11-29
NZ609727A (en) 2015-07-31
RU2015103107A3 (pt) 2018-08-20
RU2015103107A (ru) 2015-06-20
BR112013010829B8 (pt) 2021-12-21
AU2011324137B2 (en) 2015-05-07
DK2635269T3 (da) 2019-08-26
RU2707089C2 (ru) 2019-11-22
EP2635269B1 (en) 2019-05-22
US20130225685A1 (en) 2013-08-29
MX367209B (es) 2019-07-22
PH12021550804A1 (en) 2022-02-14
CO6771406A2 (es) 2013-10-15

Similar Documents

Publication Publication Date Title
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
EA202091999A3 (ru) Применение ингибиторов dpp iv
BRPI0912411A2 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
AR124497A2 (es) Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
UY33219A (es) Cetoenoles cíclicos para terapias
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
TR201906742T4 (tr) Tıbbi bir ürün ve tedavi.
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2659 DE 21/12/2021 QUANTO AO TITULO.